Lei Bao, Zhang Zhiping, Li Chunxia, Yang Jiao, Peng Jing, Zhao Yanqiu, Liu Guiming, Liang Han, Feng Jun, Xiang Xudong
Department of Thoracic Surgery, The People's Hospital of Chuxiong Yi Autonomous Prefecture, Chuxiong, China.
Department of Radiology, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
J Cancer Res Ther. 2024 Dec 1;20(7):2094-2102. doi: 10.4103/jcrt.jcrt_131_24. Epub 2025 Jan 10.
This retrospective study aimed to determine the need for lymph node resection during surgical treatment in patients with stage IA non-small-cell lung cancer (NSCLC).
A total of 1428 patients diagnosed with cT1N0M0 1 A stage NSCLC who underwent surgery were divided into two groups: lymphadenectomy (n = 1324) and nonlymphadenectomy (n = 104). The effects of lymph node resection on overall survival (OS) and recurrence-free survival (RFS) and on clinicopathological factors that affected the prognosis of the patients were investigated.
The group that underwent lymph node resection had a better 5-year OS (89.2% vs 81.1%) and 3-year RFS (87.6% vs 79.2%) than the one that did not. Multivariate Cox regression analysis revealed that the risk of OS in the nonlymphadenectomy group increased by 72% compared to that in the lymphadenectomy group [hazard ratio (HR), 1.72; 95% confidence interval (CI), 1.08-2.74; P < 0.05]. The risk of RFS in the group without lymphadenectomy increased by 45% compared to that in the group with lymphadenectomy (HR, 1.45; 95% CI, 0.98-2.14;P = 0.06). Significant reductions in the OS (HR, 5.90; 95% CI, 1.80-20.00; P < 0.005) and RFS (HR, 4.00; 95% CI, 1.50-11.00;P < 0.005) can be seen in the absence of lymph node resection in NSCLC patients with emphysema.
A thorough evaluation and removal of the hilar and mediastinal lymph nodes may prove useful in determining the cancer stage and assessing the need for further treatment, thus enhancing the prognosis of patients with stage IA NSCLC.
本回顾性研究旨在确定IA期非小细胞肺癌(NSCLC)患者手术治疗期间进行淋巴结切除的必要性。
总共1428例诊断为cT1N0M0 ⅠA期NSCLC且接受手术的患者被分为两组:淋巴结清扫组(n = 1324)和非淋巴结清扫组(n = 104)。研究了淋巴结切除对总生存期(OS)和无复发生存期(RFS)的影响,以及对影响患者预后的临床病理因素的影响。
接受淋巴结切除的组5年总生存率(89.2% 对 81.1%)和3年无复发生存率(87.6% 对 79.2%)均优于未进行淋巴结切除的组。多因素Cox回归分析显示,与淋巴结清扫组相比,非淋巴结清扫组的总生存风险增加了72%[风险比(HR),1.72;95%置信区间(CI),1.08 - 2.74;P < 0.05]。与淋巴结清扫组相比,未进行淋巴结清扫组的无复发生存风险增加了45%(HR,1.45;95% CI,0.98 - 2.14;P = 0.06)。在患有肺气肿的NSCLC患者中,未进行淋巴结切除可见总生存期(HR,5.90;95% CI,1.80 - 20.00;P < 0.005)和无复发生存期(HR,4.00;95% CI,1.50 - 11.00;P < 0.005)显著降低。
对肺门和纵隔淋巴结进行全面评估并切除可能有助于确定癌症分期和评估进一步治疗的必要性,从而改善IA期NSCLC患者的预后。